NCT06203600 2026-04-21
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
Clinical Trials
8 trialsNCT05954312 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
NCT06356311 2026-02-27
TroFuse-015
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT01196390 2026-02-18
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT06251973 2025-12-02
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT01142388 2025-11-25
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting